Upregulation of Nrf2 expression in non-alcoholic fatty liver and steatohepatitis

Hepato-Gastroenterology

Volumn 58, Issue 112, 2011, Pages 2077-2080

  Xu, Weihua ^a   Shao, Luolin ^a   Zhou, Chengjun ^b   Wang, Hongbo ^a   Guo, Jianqiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b The Fourth People s Hospital of Ji an   (China)

Author keywords

8 IsoprostaglandinF2a; Non alcoholic fatty liver; Nrf2; Oxidative stress; Steatohepatitis

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; TRANSCRIPTION FACTOR NRF2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; LIPID DIET; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; DIET, HIGH-FAT; DINOPROST; FATTY LIVER; FEMALE; MICE; NF-E2-RELATED FACTOR 2; UP-REGULATION;

EID: 84863255252     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10501     Document Type: Article

References (22)

1. Chan K, Han X, Kan Y: An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Ncad Sci USA 2001; 98:4611-4616. (Pubitemid 32295024)
2. Enomoto A, Itoh K, Nagayoshi E, et al.: High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001; 59:169-177. (Pubitemid 32117993)
3. Gong P, Cederbaum A: Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology 2006; 43:144-153. (Pubitemid 43733601)
4. Tan KP, Yang M, Ito S: Activation of Nrf2 by toxic bile acids provokes adaptive defence responses to enhance cell survival at the emergence of oxidative stress. Mol Pharmacol 2007; 72:1380-1390. (Pubitemid 350012611)
5. Xu W, Hellerbrand C, Köhler UA, Bugnon P, Kan YW, Werner S, Beyer TA: The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis[J]. Lab Invest 2008; 88(10):1068-1078.
6. Reid AE: Non-alcoholic steatohepatitis. Gastroenterology 2001; 121:711-23.
7. Kral JG, Thung SN, Biron S, et al.: Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004; 135:48-58. (Pubitemid 38041453)
8. Browning JD, Horton JD: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114:147-52. (Pubitemid 39071617)
9. Day CP, James OF: Steatohepatitis: A tale of two "hits"? Gastroenterology 1998; 114(4):842-845.
10. Day CP: Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut 2002; 50:585-8.
11. Le TH, Caldwell SH, Redick JA, et al.: The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology 2004; 39:1423-1429. (Pubitemid 38569065)
12. Biernacki WA, Kharitonov SA, Barnes PJ: Increased leukotriene B4 and 8-isoprostanein exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003; 58(4):294.
13. Morrow JD: Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans[J]. Arterioscler Thromb Vase Biol 2005; 25(2):279-286.
14. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:2467-2474. (Pubitemid 29420675)
15. Brunt EM: Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol 2005; 22:330-338.
16. Chu X, Ageishi Y, Nishimura K, Jisaka M, Nagaya T, Shono F, Yokota K: Development of enzyme-linked immunosorbent assay for 8-iso-prostaglandin F2alpha, a biomarker of oxidative stress in vivo, and its application to the quantification in aged rats. J Pharm Biomed Anal 2009; 50(5):911-6.
17. Li J, Stein T, Johnson J: Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice. Physiol Genomics 2004; 18:261-272. (Pubitemid 39319509)
18. Braun S, Hanselmann C, Gassmann M, auf dem Keller U, Born-Berclaz C, Chan K, Kan Y, Werner S: Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002; 22:5492-5505.
19. Beyer TA, Xu W, Teupser D, auf dem Keller U, Bugnon P, Hildt E, Thiery J, Kan YW, Werner S: impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J 2008; 27(1):212-23.
20. Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL, Klaassen CD: NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 2008; 325:655-664. (Pubitemid 351574806)
21. Johnson DA, Andrews GK, Xu W, Johnson JA: Activation of the antioxidatant response element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem 2002; 81:1233-1241. (Pubitemid 34809257)
22. Reisman SA, Buckley DB, Tanaka Y, Klaassen CD: CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol Appl Pharmacol 2009; 236(1):109-14.